A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria

• •Newly diagnosed and histologically confirmed glioblastoma multiforme
• •Tumor must be surgically accessible and tissue must be available
• •Age ≥ 20 years and \< 75 years
• •Life expectancy ≥ 6 months
• •Baseline MRI images must be done within 2 days after surgery
• •Patients must have a Karnofsky performances score ≥ 60 prior to treatment.
• •Patients must not have received prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors.
• •Adequate hematologic (absolute neutrophil count (ANC) ≥ 1.5x109/L, platelet count ≥ 100x109/L, hemoglobin ≥ 10 g/dL ), renal (creatinine ≤ 1.25xULN ), and hepatic function (total bilirubin ≤ 1.5xULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5xULN)
• •Women with childbearing potential must have a negative serum pregnancy test less than 7 days prior to the first dose of study drug.
• •Both men and women of reproductive potential agree to use approved contraception, such as condom and placement of an intrauterine device (IUD), during the study and until 3 months after the discontinuation of study treatment.
• •Willing and able to comply with the protocol as judged by the investigator
• •Patients must provide written consent